Location History:
- Edmonton, CA (2017 - 2022)
- London, CA (2019 - 2022)
Company Filing History:
5 out of 6 
1 out of 1 
1 out of 33 
Years Active: 2017-2025
Title: John Lewis: Innovator in Membrane Fusion and Cancer Treatment
Introduction
John Lewis is a notable inventor based in Edmonton, Canada. He has made significant contributions to the fields of biotechnology and medicine, holding a total of 7 patents. His work primarily focuses on recombinant polypeptides and methods for diagnosing and treating metastatic cancer.
Latest Patents
One of his latest patents involves recombinant polypeptides for membrane fusion. This invention discloses a recombinant polypeptide designed to facilitate membrane fusion, featuring a sequence with at least 80% identity to the ectodomain of the p14 fusion-associated small transmembrane (FAST) protein. The polypeptide includes a functional myristoylation motif, a transmembrane domain from a FAST protein, and a sequence with at least 80% identity to the endodomain of the p15 FAST protein. Additionally, a targeting ligand can be incorporated into the recombinant polypeptide for selective fusion. This polypeptide can be utilized in liposome membranes to deliver bioactive compounds, such as siRNA, or can be mixed with a lipid carrier to induce cell-cell fusion and heterokaryon formation.
Another significant patent pertains to methods for diagnosing and treating metastatic cancer. This invention outlines methods that involve detecting or modulating the expression of various genes in a biological sample from a subject. The genes include Kif3b, ACTB, SRPK1, and several others, which play a role in cancer progression.
Career Highlights
Throughout his career, John Lewis has worked with prominent organizations such as Entos Pharmaceuticals Inc. and Lawson Health Research Institute. His innovative work has contributed to advancements in therapeutic strategies and diagnostic methods in oncology.
Collaborations
John has collaborated with notable colleagues, including Roy Duncan and Eileen Kathryn Clancy. Their combined expertise has furthered the impact of his research and inventions.
Conclusion
John Lewis is a distinguished inventor whose work in recombinant polypeptides and cancer treatment methods has made a significant impact in the field of biotechnology. His contributions continue to influence research and development in medical applications.